| Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors J Strosberg, G El-Haddad, E Wolin, A Hendifar, J Yao, B Chasen, E Mittra, ... New England Journal of Medicine 376 (2), 125-135, 2017 | 2766 | 2017 |
| A meta-analysis of osteosarcoma outcomes in the modern medical era DC Allison, SC Carney, ER Ahlmann, A Hendifar, S Chawla, A Fedenko, ... Sarcoma 2012, 2012 | 470 | 2012 |
| HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal … SR Hingorani, L Zheng, AJ Bullock, TE Seery, WP Harris, DS Sigal, ... Journal of Clinical Oncology 36 (4), 359-366, 2018 | 447 | 2018 |
| Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial MJ Pishvaian, EM Blais, JR Brody, E Lyons, P DeArbeloa, A Hendifar, ... The Lancet Oncology 21 (4), 508-518, 2020 | 406 | 2020 |
| Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the phase III NETTER-1 trial J Strosberg, E Wolin, B Chasen, M Kulke, D Bushnell, M Caplin, RP Baum, ... Journal of Clinical Oncology 36 (25), 2578, 2018 | 365 | 2018 |
| A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group … PL Kunz, PJ Catalano, H Nimeiri, GA Fisher, TA Longacre, CJ Suarez, ... Journal of Clinical Oncology 36 (15_suppl), 4004-4004, 2018 | 289* | 2018 |
| Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma E Van Cutsem, MA Tempero, D Sigal, DY Oh, N Fazio, T Macarulla, ... Journal of Clinical Oncology 38 (27), 3185, 2020 | 283 | 2020 |
| Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas OA Zill, C Greene, D Sebisanovic, LM Siew, J Leng, M Vu, AE Hendifar, ... Cancer discovery 5 (10), 1040-1048, 2015 | 273 | 2015 |
| Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers AD Singhi, B George, JR Greenbowe, J Chung, J Suh, A Maitra, ... Gastroenterology 156 (8), 2242-2253. e4, 2019 | 266 | 2019 |
| Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity D Yang, A Hendifar, C Lenz, K Togawa, F Lenz, G Lurje, A Pohl, T Winder, ... Journal of gastrointestinal oncology 2 (2), 77, 2011 | 258 | 2011 |
| 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long … JR Strosberg, ME Caplin, PL Kunz, PB Ruszniewski, L Bodei, A Hendifar, ... The Lancet Oncology 22 (12), 1752-1763, 2021 | 236 | 2021 |
| Gender disparities in metastatic colorectal cancer survival A Hendifar, D Yang, F Lenz, G Lurje, A Pohl, C Lenz, Y Ning, W Zhang, ... Clinical Cancer Research 15 (20), 6391-6397, 2009 | 232 | 2009 |
| Neuroendocrine tumors of the lung: current challenges and advances in the diagnosis and management of well-differentiated disease AE Hendifar, AM Marchevsky, R Tuli Journal of thoracic oncology 12 (3), 425-436, 2017 | 227 | 2017 |
| Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative MJ Pishvaian, RJ Bender, D Halverson, L Rahib, AE Hendifar, S Mikhail, ... Clinical Cancer Research 24 (20), 5018-5027, 2018 | 210 | 2018 |
| Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation RT Shroff, A Hendifar, RR McWilliams, R Geva, R Epelbaum, L Rolfe, ... JCO precision oncology 2, 1-15, 2018 | 187 | 2018 |
| Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination J Gong, TQ Le, E Massarelli, AE Hendifar, R Tuli Journal for immunotherapy of cancer 6, 1-17, 2018 | 173 | 2018 |
| Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial V Chung, S McDonough, PA Philip, D Cardin, A Wang-Gillam, L Hui, ... JAMA oncology 3 (4), 516-522, 2017 | 169 | 2017 |
| Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma SP Chawla, LD Cranmer, BA Van Tine, DR Reed, SH Okuno, JE Butrynski, ... Journal of Clinical Oncology 32 (29), 3299, 2014 | 165 | 2014 |
| Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer G Lurje, W Zhang, AM Schultheis, D Yang, S Groshen, AE Hendifar, ... Annals of Oncology 19 (10), 1734-1741, 2008 | 160 | 2008 |
| Pancreas cancer‐associated weight loss AE Hendifar, MQB Petzel, TA Zimmers, CS Denlinger, LM Matrisian, ... The oncologist 24 (5), 691-701, 2019 | 154 | 2019 |
